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Abstract: 
Over 90 million patients have been prescribed clopidogrel since its FDA approval in 
1997.  Clopidogrel hypersensitivity affects 6% of patients, most commonly in the form of 
a pruritic rash.  Symptoms are severe enough to result in drug discontinuation in 1.5%.  
Premature discontinuation of clopidogrel is problematic after percutaneous coronary 
intervention because of the risk of stent thrombosis and death.  Accordingly, the 
management of patients with clopidogrel hypersensitivity is of significant clinical 
importance.  Conventional clopidogrel desensitization protocols have been successful, 
but require a washout period off medication to enable accurate detection of reaction to 
during desensitization.  This technique is therefore undesirable in patients following stent 
placement.  Clopidogrel hypersensitivity can be successfully treated without drug 
interruption using short-course corticosteroids and antihistamines to enable development 
of physiologic tolerance while the medication is continued. The role of newer agents, 
such as prasugrel, as surrogate therapy in patients with clopidogrel hypersensitivity is yet 
to be defined. 
 
Short title:  Clopidogrel Hypersensitivity 
Keywords:  clopidogrel, hypersensitivity, drug allergy, anti-platelet therapy, 
desensitization, thienopyridine.  
Clopidogrel is the most frequently prescribed antiplatelet therapy, with more than 
9.1 million prescriptions filled in 2008.  Clopidogrel, a member of the thienopyridine 
class of antiplatelet agents, directly inhibits adenosine diphosphate (ADP)-induced 
platelet aggregation by irreversibly binding the P2Y12 receptor.  The oral prodrug is 
converted into the active metabolite by the cytochrome P-450 pathway in the liver.  
Clopidogrel has become widely prescribed for prevention of vascular events following 
myocardial infarction (MI), cerebrovascular accident (CVA), and in patients with known 
peripheral arterial disease (PAD).   
Several large studies have demonstrated the benefits of clopidogrel therapy 
following MI and stroke.  The Clopidogrel versus Aspirin in Patients at Risk of Ischemic 
Events (CAPRIE) trial randomized 19,185 patients with recent MI, CVA, or documented 
PAD to receive either clopidogrel 75mg daily or aspirin 325 mg daily [1].  Clopidogrel 
was associated with an 8.7% relative risk reduction in the composite endpoint of stroke, 
MI, or vascular death.  The Clopidogrel in Unstable Angina to Prevent Recurrent Events 
(CURE) trial demonstrated further benefit from clopidogrel in combination with aspirin 
[2]. In this study, 12,562 patients with non-ST elevation acute coronary syndrome were 
randomized to either clopidogrel 75mg daily or placebo in addition to aspirin therapy.   
Compared to aspirin monotherapy, dual antiplatelet therapy resulted in 20% relative risk 
reduction in the composite endpoint of cardiovascular death, nonfatal MI, and nonfatal 
CVA.  
Clopidogrel is also widely prescribed in combination with aspirin following 
percutaneous coronary intervention (PCI) for the prevention of stent thrombosis.  
Premature discontinuation of dual antiplatelet therapy following PCI is the most 
important clinical predictor of acute stent thrombosis.  Early thienopyridine 
discontinuation is associated with a 30-fold rise in subacute stent thrombosis, which 
typically results in MI and is associated with a 20 to 45% mortality [3,4,5,6].  The 
Clopidogrel Aspirin Stent International Cooperatives Study (CLASSICS) and Ticlid or 
Plavix Post Stent (TOPPS) trials showed clopidogrel was non-inferior to ticlopidine in 
reducing major adverse cardiovascular events (MACE) and acute stent thrombosis [7,8].  
Because of its improved safety profile, clopidogrel quickly replaced ticlopidine as the 
thienopyridine of choice following PCI.  With the advent of drug-eluting stents, and the 
Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trial, the 
recommended duration of clopidogrel therapy following PCI has increased from the 
initial 4 weeks to a minimum of 12 months [9]. 
 
Clopidogrel hypersensitivity   
Allergic reaction to clopidogrel most frequently presents as pruritic rash and 
occurs in 4-6% of patients receiving clopidogrel [1,10].  Rash is severe enough to result 
in drug discontinuation in 1.5% of patients [1].  More severe hypersensitivity syndromes 
have been reported including febrile illness [11,12], leucopenia [13,14], thrombotic 
thrombocytopenic purpura [15,16,17,18], aplastic anemia [19,20,21,22], angioedema 
[23], serum sickness [24], systemic inflammatory response syndrome [25], and end organ 
injury [26].  These more serious hypersensitivity reactions are rare, and morbiliform rash 
remains the most frequently encountered reaction to clopidogrel therapy.  
 In the largest published case series of 24 consecutive patients presenting with 
clopidogrel hypersensitivity, von Tiehl et al observed that the median onset of 
hypersensitivity symptoms was 6 days after initiation of therapy [27].  The rash was 
macular and erythematous, beginning on the face, chest or abdomen.  With progression, it 
became a confluent generalized rash that involved the palms and soles in 29% of patients.  
Similar observations were made in our cohort of 20 patients experiencing clopidogrel 
hypersensitivity after undergoing PCI [28].  Mean onset of symptoms was 6 ± 2 days 
after clopidogrel exposure.  The distribution of time to onset of hypersensitivity 
symptoms is shown in Figure 1.  Ninety percent of these patients presented with the 
typical erythematous pruritic rash described by von Tiehl.  Additional symptoms of 
clopidogrel hypersensitivity observed in this cohort included non-pruritic rash and 
angioedema [28]. 
 Diagnosing clopidogrel hypersensitivity can be challenging.  Antibody-based 
laboratory assays for clopidogrel hypersensitivity are not available.  Clinically, the 
diagnosis can be made from symptom resolution with drug discontinuation and 
recurrence with repeat challenge.  Clopidogrel hypersensitivity typically presents during 
the first two weeks of therapy, coinciding with the time of highest risk for stent 
thrombosis.   In this setting of recent PCI, clopidogrel discontinuation carries a 25-29% 
risk for stent thrombosis [4,6].  Therefore, clinical diagnosis must often be made based on 
history and temporal relationship to onset of symptoms.  Definitive clinical diagnosis is 
further complicated by the concomitant introduction of multiple medications, iodinated 
contrast, and drug impregnated polymer stents.   
The exact mechanism of clopidogrel hypersensitivity is not clearly understood.  
True hypersensitivity reactions result from an IgE-mediated immunologic response to an 
antigen.  Vigo et al report a case of clopidogrel hypersensitivity in a patient with a 
positive intradermal skin test response to clopidogrel [29].  Skin biopsies in clopidogrel 
hypersensitivity reveal nonspecific findings compatible with drug eruption [11].  This 
would suggest an IgE-mediated process.  However, there may also be a role for direct 
mast-cell or complement activation, immune complex formation, or T-cell activation by 
clopidogrel or one of its metabolites.   
   
Pharmacologic alternatives to clopidogrel 
 Dual anti-platelet therapy with aspirin and clopidogrel has become the standard of 
care after PCI with stent placement [30].  For patients with allergy to clopidogrel, 
therapeutic alternatives are limited.  Until recently, ticlopidine was the only alternative 
thienopyridine class antiplatelet agent available.  Ticlopidine, like clopidogrel, is proven 
efficacious in reducing bare metal stent thrombosis and preventing cardiovascular events 
after stroke [31,32,33].  There is limited data on the use of ticlopidine with drug-eluting 
stents [34].  The clinical utility of ticlopidine is limited by the occurrence of 
gastrointestinal side effects, neutropenia, thrombocytopenia, and rash.  Up to 21% of 
patients on ticlopidine discontinue therapy due to these side effects [31,33,35].  
Neutropenia occurs in 2.4% of patients [35], and thrombotic thrombocytopenic purpura 
(TTP) has been reported with an incidence of 0.02% [36].  As a result of these 
hematologic side effects, CBC monitoring every 2 weeks is necessary for patients 
receiving ticlopidine. 
 In July 2009 the FDA approved prasugrel, the newest thienopyridine and 
alternative to clopidogrel therapy.  In TRITON-TIMI 38, prasugrel was associated with a 
19% relative risk reduction in cardiovascular death, nonfatal MI, and nonfatal CVA 
compared to clopidogrel.  This reduction in cardiovascular events was counter-balanced 
by an increase in the risk of life-threatening bleeding (1.4% versus 0.9%) [37].  In 
patients with history of transient ischemic attack or stroke, the risk of intra-cranial 
hemorrhage overpowered the benefits of prasugrel.  The use of prasugrel is 
contraindicated in these patients.  Additional groups at increased risk for bleeding with 
prasugrel include patients greater than 75 years of age, less than 60 kg in weight, and 
those who have propensity to bleed or require use of other medications increasing the risk 
of bleeding [38]. 
 Cross-reactivity between clopidogrel and ticlopidine has been described in several 
case reports [27,39,40,41].  The two medications differ only by the substitution of a 
carboxymethyl side group on clopidogrel [42].  The chemical structures of the clinically 
available thienopyridine antiplatelet agents are shown in Figure 2.  It is unclear which 
moiety of the clopidogrel and ticlopidine stimulates the allergenic response.  Whether this 
cross-reactivity carries over to prasugrel has yet to be determined and the use of this new 
agent in patients with clopidogrel hypersensitivity has not been reported. 
 For patients in whom alternative thienopyridine class antiplatelet agents are 
contraindicated, there is no proven non-thienopyridine therapeutic alternative. The use of 
warfarin with aspirin for bare metal stents was evaluated in the Full Anticoagulation 
versus Aspirin and Ticlopidine (FANTASTIC) study [43].  This study randomized 485 
patients to receive either ticlopidine 250 mg twice daily or warfarin adjusted to an INR of 
2.5-3.0 for 6 weeks after PCI.  Warfarin therapy resulted in a 50% increase in bleeding 
complications without affecting the rate of MI, death, or stent occlusion.  In a second 
trial, 517 patients were randomized to warfarin or ticlopidine plus aspirin [44].  A higher 
incidence of cardiac events was noted in the warfarin group in addition to the previously 
seen increase in hemorrhagic events and vascular complications.   
The largest trial, Stent Anticoagulation Restenosis Study (STARS), enrolled 1653 
patients and compared aspirin, aspirin with ticlopidine, and aspirin with warfarin [31].  
Aspirin monotherapy and in combination with warfarin were both inferior to aspirin with 
ticlopidine in reducing major adverse cardiac events and stent thrombosis.  The risk of 
hemorrhagic complications was highest in those patients receiving anticoagulation with 
warfarin.  Although warfarin with aspirin was used before thienopyridines were 
available, these studies have established that warfarin is inferior to dual antiplatelet 
therapy in the reduction of cardiovascular events following PCI. 
Several randomized trials have investigated cilostazol as an alternative to 
thienopyridines in patients receiving bare metal stents. The Randomized Prospective 
Antiplatelet Trial of Cilostazol versus Ticlopidine in Patients Undergoing Coronary 
Stenting (RACTS) evaluated ticlopidine 250mg twice daily or cilostazol 100mg twice 
daily in 397 patients [45].  At 9 months, there was no significant difference in death, MI, 
stroke, and stent thrombosis.  A second trial by Lee et al found similar results comparing 
cilostazol against clopidogrel [46].  They observed no significant difference in target-
lesion revascularization or drug-related adverse events.  In a third trial comparing 
cilostazol versus ticlopidine, there was no significant difference at 6 months in restenosis 
or coronary angiographic result [47].  However, at 3 years, the group treated with 
cilostazol experienced significantly less death, MI, stent thrombosis, revascularization, 
and CVA.  There is limited data on the use of cilostazol following drug eluting stent 
placement.  The use of cilostazol is contraindicated in patients with heart failure, and 
caution must be used in patients who take inhibitors of the cytochrome P450 system. 
  
Clopidogrel desensitization 
 The mechanism of drug desensitization is complex and has yet to be fully 
elucidated.  One theory relates the success of desensitization to alterations in the balance 
of circulating IgE and IgG levels [48].  Following antigen exposure, there is a transient 
rise in IgE antibodies, but also a rise in levels of IgG antibodies.  These allergen-specific 
IgG antibodies activate a negative feedback loop inhibiting IgE-dependent histamine 
release by basophils and T cell activation.  Desensitization also appears to shift the 
balance of T helper cells towards a Th1 population and away from the Th2 subtype that 
drives allergen responses [48].   A second theory proposes a state of mast cell 
unresponsiveness develops from gradual antigen exposure.  By supplying antigen in 
small incremental doses, the IgE receptors are slowly bound and occupied without 
triggering mast cell activation [40]. Likely, both of these pathways contribute to the 
success of desensitization. 
 Traditional desensitization protocols, similar to those used for aspirin and 
antibiotics, have been used with success in patients with clopidogrel hypersensitivity 
(Table 1).  These protocols rely on withdrawal of clopidogrel to allow hypersensitivity 
symptoms to resolve prior to initiation of desensitization.  Beta blockers, antihistamines, 
and steroids are held for 48-96 hours before desensitization.  Patients are administered 
escalating doses of clopidogrel starting at 0.005 to 0.02mg and doubling every 15 to 30 
minutes until the target dose of 75mg is achieved.  If hypersensitivity symptoms recur 
during desensitization, symptoms are treated and protocol is held until symptoms resolve.  
The protocol is resumed by repeating the inciting dose.  Desensitization is typically 
completed in 3-8 hours. 
 The first case report of successful clopidogrel desensitization was presented at the 
American College of Allergy, Asthma, and Immunology Annual Meeting in 2004.  Vigo 
et al describe a patient who experienced typical clopidogrel hypersensitivity rash on the 
5th day of clopidogrel therapy [29]. Skin testing confirmed a reaction to clopidogrel and 
the patient was successfully desensitized with escalating doses of clopidogrel starting at 
0.02mg and administered every 15 minutes.   
During the same time, Camara and Almeda were successfully desensitizing 
patients using an 8-hour protocol starting at 0.005mg and administering escalating doses 
of clopidogrel every 30 minutes.  They report on successful inpatient and outpatient 
desensitization in 3 patients presenting with clopidogrel hypersensitity rash [40].  Two of 
the three patients in this case-series had experienced hypersensitivity with both 
clopidogrel and ticlopidine, necessitating desensitization.  Following this same protocol, 
Lee-Wong was able to reproduce their success with clopidogrel desensitization on an 
additional patient [49]. All subsequent desensitization protocols have been modifications 
derived from the protocols described by Vigo or Camara and Almeda. 
 Walker et al described their experiences in 8 patients with an accelerated 3 hour 
desensitization protocol at their institution [39].  Based on the findings of Vigo, they 
started desensitization with a dose of 0.02mg and administered escalating 2-fold dosages 
every 15 minutes in a monitored ICU setting.  In contrast to previous desensitization 
protocols that restricted treatment to patients with cutaneous manifestations of 
hypersensitivity, they included 2 patients experiencing more the more severe 
hypersensitivity reaction of angioedema.   All 8 patients were successfully desensitized 
without major adverse events.  A follow-up report described further success in 
desensitization of an additional 5 patients [50].   
The largest published case series involved 24 consecutive patients with 
clopidogrel hypersensitivity following drug-eluting stent implantation [27].  Patients were 
desensitized by von Tiehl et al using an 8-hour protocol modified from Camara and 
Almeda [40].  In contrast to other case reports, patients were bridged through the washout 
period using ticlopidine, a thienopyridine similar in structure to clopidogrel.  At least one 
of the patients experienced similar hypersensitivity reaction to ticlopidine.  
Desensitization was performed starting at a dose of 0.005mg with incremental doubling 
doses administered every 30 minutes.  Initial desensitization was successful in all 
patients, with 4 of the 24 patients requiring treatment for cutaneous reactions during 
desensitization.  Two patients (8%) required repeat desensitization – one for persistent 
rash, and one for recurrent rash following 3 days of noncompliance. Since von Tiehl’s 
published case series, additional case reports continue to demonstrate the success of this 
desensitization protocol [51,52].   
Traditional escalating dose desensitization protocols have been shown effective in 
treating clopidogrel hypersensitivity manifest as cutaneous rash and angioedema.  There 
have been no reports using this technique in patients whom experience gastrointestinal or 
hematologic side effects, anaphylaxis, or systemic hypersensitivity syndromes.  In the 
appropriately selected patient, this desensitization protocol can be safely performed in the 
outpatient setting [27,50]. 
 
Management of hypersensitivity reaction without clopidogrel interruption 
 In a retrospective analysis at our institution, 20 patients were identified that 
experienced clopidogrel hypersensitivity following bare metal or drug eluting stent 
implantation [28].  The most common symptom was rash, but one patient presenting with 
angioedema was included.  In a novel approach, patients were treated for their 
hypersensitivity symptoms without interrupting clopidogrel therapy.  Treatment regimen 
included antihistamines alone in 5 patients, corticosteroids alone in 4 patients, and 
combination of antihistamines and corticosteroids in 11 patients.  The most commonly 
prescribed corticosteroid regimen was a 6 day solumedrol taper (Medrol Dosepak), with 
the mean corticosteroid therapy duration being 9 ± 6 days (range 6-20). 
 Treatment of clopidogrel hypersensitivity with antihistamines and short-course 
corticosteroids was successful in 17 patients (85%).  Most patients were successfully 
treated as outpatients (80%).  Two patients experienced recurrence of their symptoms, 
which were successfully treated with a longer corticosteroid taper and the addition of a 
leukotriene inhibitor.  The three patients in whom this approach was unsuccessful 
included one patient with angioedema, one patient with progression to desquamation, and 
one patient with intolerable pruritis. 
 The 17 patients who were successfully treated were able to complete the 
minimum recommended duration of clopidogrel therapy without drug interruption.  The 
mean duration of clopidogrel therapy in these patients is 388 ± 272 days, with 843 days 
being the longest duration of clopidogrel therapy.  As of last follow-up, 60% of these 
patients remained on long-term clopidogrel therapy. There was no stent thrombosis, 
death, myocardial infarction, or stroke during treatment or follow-up.   
 In a similar strategy, Cheema et al treated 25 patients presenting with clopidogrel 
hypersensitivity rash with oral corticosteroids while continuing clopidogrel therapy [53].  
Patients completed a 2 week tapering course of prednisone starting at 30mg twice daily.  
All 25 patients were successfully treated, without recurrence of symptoms.  By 
suppressing the symptoms of clopidogrel hypersensitivity with antihistamines and 
corticosteroids, patients are able to develop physiologic tolerance without interrupting 
clopidogrel therapy.  These two series suggest short-course corticosteroids and 
antihistamines offer a safe and effective alternative to traditional desensitization 
protocols.  This method appears to allow the development of physiologic tolerance 
without interrupting drug therapy.  Our current approach at the Thomas Jefferson 
University Hospital for management of clopidogrel hypersensitivity is summarized in 
Table 2. 
 
Expert commentary 
Diagnosing hypersensitivity is complex, with new medications and drug 
impregnated polymer stents frequently introduced during the same admission following a 
cardiovascular event.  Both immunological and non-immunological mechanisms 
contribute to adverse drug events, and the exact pathophysiology of hypersensitivity 
remains unknown.  In most cases there are no reliable diagnostic tests beyond drug 
challenge and history.  In hypersensitivity reactions that develop shortly after stent 
implantation, it is often difficult to distinguish between the stent, aspirin, or clopidogrel 
as the source of the reaction.  One must heavily rely on clinical history for the 
identification of the inciting agent in this population. 
The management of clopidogrel hypersensitivity is challenging, particularly in the 
post PCI population.  In patients receiving clopidogrel for secondary cardiovascular 
prevention, traditional desensitization protocols are highly successful to enable 
resumption of clopidogrel therapy.  In contrast, PCI patients typically experience 
hypersensitivity during the first two weeks of clopidogrel therapy when drug 
discontinuation carries the greatest risk for stent thrombosis.  In this population, a 
traditional desensitization protocol incorporating a pharmacologic wash out period is a 
less viable option.  Treatment of clopidogrel hypersensitivity with tapering doses of 
corticosteroids and antihistamines is successful in 85-100% of cases, and appears to be as 
successful as traditional desensitization protocols. 
With the FDA approval of prasugrel, there is now a more viable alternate 
thienopyridine class antiplatelet agent.  Use of ticlopidine, the first available 
thienopyridine, was clinically limited by frequent side effects and adverse reactions.  
Although still available by prescription, ticlopidine is often not tolerated long enough to 
complete adequate therapy following drug-eluting stent placement.  Prasugrel is more 
efficacious than clopidogrel in reducing cardiovascular death, MI, and stroke but incurs a 
higher risk of bleeding.  For this reason, it is not a therapeutic option in patients with 
prior cerebrovascular events.  Cross-reactivity among thienopyridines further limits the 
use of therapeutic alternatives in clopidogrel hypersensitivity. Use of cilostazol or 
warfarin as sufficient alternatives to thienopyridine therapy has not been established. 
In the post PCI population, treatment of clopidogrel hypersensitivity with 
corticosteroids and antihistamines remains a viable option, especially in patients unable 
or ineligible to take the alternative thienopyridine prasugrel.  The elimination of the 
washout period avoids the risk of catastrophic stent thrombosis due to early 
discontinuation of antiplatelet therapy.  Successful treatment enables long-term 
continuation of therapy and confers a low risk of adverse cardiovascular events.  Life-
threatening or severe hypersensitivity syndromes including Stevens - Johnson syndrome 
and anaphylaxis should prompt consideration of the risks and benefits of desensitization 
versus alternative therapies. 
  
Five-year view  
Newly available in the U.S., prasugrel is a viable alternative to clopidogrel in 
patients without a history of cerebrovascular event, low body mass, or advanced age.  As 
Sanofi Aventis’s patent for clopidogrel bisulfate expires in November 2011, generic 
equivalents of clopidogrel will become available in the United States.  With the 
advantage of reduced cost and lower incidence of bleeding, it will likely remain first line 
therapy in the prevention of stent thrombosis and prevention of secondary cardiovascular 
events over alternative thienopyridines.  Furthermore, the use of clopidogrel may be 
extended in the future should prolonged thienopyridine therapy (beyond one year) prove 
to be beneficial in patients with drug-eluting stents.  
 It is reasonable to expect some cross-hypersensitivity between clopidogrel and 
prasugrel, as has been documented to occur with ticlopidine.  As prescriptions for 
clopidogrel rise, more physicians including family practitioners, internist, neurologists, 
and cardiologists will be faced with treating clopidogrel hypersensitivity.  As clinicians, 
we will continue to face the challenges of clopidogrel hypersensitivity and the 
complexities of its management.  Further studies will be necessary to determine if 
prasugrel is a safe and effective substitute for clopidogrel in patients with hypersensitivity 
reactions. 
The mechanisms of drug hypersensitivity are complex and not fully understood.  
IgE mediated mast cell response is believed to play a role in the process.  Escalating dose 
desensitization protocols are an effective means of overcoming hypersensitivity reactions.  
The mechanism of desensitization to achieve tolerance remains speculation.  The success 
of the approach of enabling the development of physiology tolerance while continuing 
drug therapy raises the possibility of alternative pathways to drug desensitization.  As this 
technique is proven successful in the management of clopidogrel hypersensitivity, it may 
be applicable in the future to other drug hypersensitivities.   
 
Key Issues 
• Clopidogrel, a thienopyridine class antiplatelet agent, remains a mainstay in the 
medical therapy for prevention of stent thrombosis and secondary cardiovascular 
events. 
• Hypersensitivity to clopidogrel often manifests as a macularpapular rash starting 
on the trunk and spreading to the extremities, starting approximately a week after 
initiation of clopidogrel. 
• Other thienopyridines include ticlopidine and recently prasugrel.  Ticlopidine is 
poorly tolerated due to GI side effects and neutropenia, and prasugrel is 
associated with increased risk of bleeding. 
• Non-thienopyridine alternatives including aspirin monotherapy and warfarin 
appear inferior to regimens including thienopyridines in the post PCI population. 
• Traditional desensitization protocols utilizing a washout period are successful, but 
potentially expose patients to an increased risk of stent thrombosis.  
• Future research will elucidate the mechanisms of drug hypersensitivity and the 
mechanism by which desensitization is effective. 
• A novel approach to treating clopidogrel hypersensitivity with antihistamines and 
short-course corticosteroids is successful at enabling patients to develop 
physiologic tolerance without interruption in drug therapy. 
• Application of this approach to other drug hypersensitivities will determine if this 
method of management is unique to clopidogrel hypersensitivity or can be applied 
to the management of other hypersensitivity reactions. 
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